0001179110-17-012520.txt : 20170920
0001179110-17-012520.hdr.sgml : 20170920
20170920173944
ACCESSION NUMBER: 0001179110-17-012520
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170918
FILED AS OF DATE: 20170920
DATE AS OF CHANGE: 20170920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haviland Kate
CENTRAL INDEX KEY: 0001663022
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 171094702
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORPORATION
STREET 2: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2017-09-18
0
0001597264
Blueprint Medicines Corp
BPMC
0001663022
Haviland Kate
C/O BLUEPRINT MEDICINES CORPORATION
38 SIDNEY STREET, SUITE 200
CAMBRIDGE
MA
02139
0
1
0
0
Chief Business Officer
Common Stock
2017-09-18
4
M
0
6356
16.28
A
6356
D
Common Stock
2017-09-18
4
S
0
6356
60.03
D
0
D
Stock Option (Right to Buy)
16.28
2017-09-18
4
M
0
6356
0
D
2026-02-01
Common Stock
6356
107308
D
The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.20 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
/s/ Christopher Frankenfield, Attorney-in-Fact
2017-09-18